HIV-Associated Neurocognitive Disorders

1. An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS<br>2. Central Nervous System Complications of Human Immunodeficiency Virus Infection<br>3. Health LIteracy in HIV-associated Neurocognitive Disorders<br>4. Neuroimaging insights into the CNS effects of HIV infection<br>5. Early and upstream subcellular organellar events associated with HAND<br>6. White matter loss and oligodendrocyte dysfunction in HAND<br>7. Pathogenesis of HIV-associated pain<br>8. Neuropathogenesis of HIV-associated neuropathic pain<br>9. Neuropathic Pain in HIV and the role of the Autophagy pathway<br>10. Host peripheral immune dynamics increase HIV-associated neurocognitive disorders incidence and progression<br>11. The role of immunometabolism in HIV associated depression and cognitive impairment<br>12. Role of extracellular viral regulatory proteins in neuropathogenesis<br>13. Role of inflammasomes in HIV-1 and drug abuse-mediated neuroinflammation<br>14. The Contribution of Myeloid Cells to HIV Neuropathogenesis<br>15. Immunophilin ligands modulate phagocytosis and viral replication in HIV-infected macrophages<br>16. Immunometabolic mechanisms of HIV-associated neurocognitive disorders and traumatic brain injury: Commonalities and contrasts between chronic and acute neurodegenerative pathologies<br>17. Endolysosome dysfunction in HAND<br>18. Evolving biomarkers for HIV-associated neurocognitive disorders (HAND)<br>19. Intracellular immunity against HIV infection<br>20. NeuroHIV and the Glymphatic System<br>21. The p75 neurotrophin receptor: emerging role in the pathogenesis of mature synapses in Human Immunodeficiency Virus-Associated Neurocognitive Disorders<br>22. The Role of HIV-Associated Neuroendocrine Dysfunction in HAND<br>23. Impact of SARS-CoV-2/COVID-19 on HIV-1-associated neurocognitive disorders<br>24. Molecular mechanisms of dopaminergic transmission in NeuroHIV<br>25. The effect of substance misuse on HIV persistence in the CNS: epidemiological, immunological, and molecular considerations<br>26. Extracellular vesicles in alcohol- and tobacco-induced neuroAIDS<br>27. NeuroHIV in the context of opioid use disorder: A complex and evolving relationship<br>28. Impairment of cholesterol homeostasis induced by Nef-containing extracellular vesicles as a factor in HAND pathogenesis<br>29. Long noncoding RNAs in immune response, viral infection, and opioid use<br>30. Using cross-species behavioral tools to determine mechanisms contributing to HIV associated neurological disorders and comorbid substance use<br>31. Therapeutic potential of Curcumin in treating HIV-1 associated neurocognitive disorders<br>32. Targeting the Endocannabinoid System in HAND<br>33. Predicting the effectiveness of combination treatment of Dolutegravir and Fluoxetine for Depressive disorders in HIV<br>34. ANTIRETROVIRAL THERAPY AND ITS CEREBRAL VASCULAR TOXICITY<br>35. Strategies for HIV-1 Elimination